A Phase 4 interventional study of PCV13 in Asplenia and β-thalassemia Major, sponsored by Aghia Sophia Children's Hospital of Athens. Status unknown at 1 site in Greece. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2013-05-06.
Sponsored by Aghia Sophia Children's Hospital of Athens · Phase 4, Interventional, and Prevention
Among 26 studies in beta-Thalassemia with a site in Greece — 3 open to participants now, 7 under way, 3 of them phase 3. beta-Thalassemia · Greece.
Among the 26 studies in beta-Thalassemia with a site in Greece, this one is the 14th largest by enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2010, is one of 2 in phase 4, and was the 8th registered.
294 studies on the registry are indexed under beta-Thalassemia; 69 are open to participants now.
Browse beta-Thalassemia studies →3 of the 26 studies in beta-Thalassemia with a site in Greece are open now. Recruiting first, the newest first:
Cyprus Institute of Neurology and Genetics · Sites in Greece, United States, Angola and 13 more countries
Ages 2+
Celgene · Sites in Greece, United States, China and 6 more countries
Ages 6–17
Celgene · Sites in Greece, United States, Australia and 19 more countries
Ages 18+
A study can be open while its sites in Greece have not opened yet or have stopped. Only those recruiting at a site in Greece →
Of the 43 beta-Thalassemia studies recruiting now, 10 (23%) set no upper age limit and 31 (72%) stop at 75 or younger; 34 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 37 is close to the median of 40 across 208 interventional studies indexed under beta-Thalassemia.
Median enrollment 62 across the 22 interventional studies, 83 across the 4 observational. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 26 have an industry lead sponsor. The 10 most frequent:
Aghia Sophia Children's Hospital of Athens is the lead sponsor of 5 studies on the registry; none are open to participants now.
Aghia Sophia Children's Hospital of Athens has 1 study filed under beta-Thalassemia — fewer than ten, so there is no comparison to draw.
2 of the studies in beta-Thalassemia with a site in Greece that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06421636Regeneron PharmaceuticalsA Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body | 2026-12-03 |
| NCT05799118Cyprus Institute of Neurology and GeneticsStudy of the Role of Genetic Modifiers in Hemoglobinopathies | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 26 studies in beta-Thalassemia with a site in Greece, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether one dose of the 13-valent pneumococcal conjugate vaccine (PCV13) induces immunological memory in asplenic adults and whether previously administered immunizations with the 23-valent polysaccharide pneumococcal vaccine influence the cellular immune response to PCV13 in this group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Biological: PCV13
immunoglobulin G (IgG) B memory cell response one month post vaccination (measured by ELISpot)
Time frame: One month post-PCV13
immunoglobulin M (IgM) B memory cell response one month post vaccination (measured by ELISpot)
Time frame: one month post PCV13
Maintenance of B memory cells three years after PCV13 vaccination
Time frame: three years after study vaccination
The record gives a start of Oct 2010 and a primary completion of Feb 2012. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in May 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 13-valent pneumococcal vaccine
Aghia Sophia Children's Hospital of Athens